Literature DB >> 10773538

18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG.

L Varagnolo1, M P Stokkel, U Mazzi, E K Pauwels.   

Abstract

This article reviews possible use of (18)F-labelled radiopharmaceuticals in oncology with positron emission tomography. The characteristics of various (18)F-labelled compounds are proteins and peptides, those that bind to. receptors, agents to assess hypoxia, and agents to evaluate gene therapy are highlighted. Furthermore, different (18)F-labelled tissue specific agents are indicated for the detection and monitoring of various malignancies: melanoma, brain tumours, breast cancer, prostate cancer and colorectal cancer. (18)F-fluorodeoxyglucose has been excluded from this summary.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10773538     DOI： 10.1016/s0969-8051(99)00109-2

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  11 in total

1.  PET imaging of bacterial infections with fluorine-18-labeled maltohexaose.

Authors:  Xinghai Ning; Wonewoo Seo; Seungjun Lee; Kiyoko Takemiya; Mohammad Rafi; Xuli Feng; Daiana Weiss; Xiaojian Wang; Larry Williams; Vernon M Camp; Malveaux Eugene; W Robert Taylor; Mark Goodman; Niren Murthy
Journal:  Angew Chem Int Ed Engl       Date:  2014-10-21       Impact factor: 15.336

2.  Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry.

Authors:  Mohammad Namavari; Omayra Padilla De Jesus; Zhen Cheng; Abhijit De; Ernest Kovacs; Jelena Levi; Rong Zhang; Joshua K Hoerner; Hans Grade; Faisal A Syud; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2008-05-15       Impact factor: 3.488

Review 3.  Multimodality imaging: an update on PET/CT technology.

Authors:  Osama Mawlawi; David W Townsend
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

4.  Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.

Authors:  Mindy D Szeto; Gargi Chakraborty; Jennifer Hadley; Russ Rockne; Mark Muzi; Ellsworth C Alvord; Kenneth A Krohn; Alexander M Spence; Kristin R Swanson
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

5.  Flow optimization study of a batch microfluidics PET tracer synthesizing device.

Authors:  Arkadij M Elizarov; Carl Meinhart; Reza Miraghaie; R Michael van Dam; Jiang Huang; Antoine Daridon; James R Heath; Hartmuth C Kolb
Journal:  Biomed Microdevices       Date:  2011-02       Impact factor: 2.838

Review 6.  Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer.

Authors:  F Berger; S S Gambhir
Journal:  Breast Cancer Res       Date:  2000-12-11       Impact factor: 6.466

7.  Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma.

Authors:  I Al Jammaz; B Al-Otaibi; Y Al-Malki; A Abousekhrah; S M Okarvi
Journal:  EJNMMI Radiopharm Chem       Date:  2021-03-18

Review 8.  PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective.

Authors:  Sridhar Goud Nerella; Priti Singh; Tulja Sanam; Chander Singh Digwal
Journal:  Front Med (Lausanne)       Date:  2022-02-28

9.  [Not Available].

Authors:  Franziska Graf; Lena Koehler; Torsten Kniess; Frank Wuest; Birgit Mosch; Jens Pietzsch
Journal:  J Oncol       Date:  2009-06-17       Impact factor: 4.375

Review 10.  Microfluidics for synthesis of peptide-based PET tracers.

Authors:  Yang Liu; Mei Tian; Hong Zhang
Journal:  Biomed Res Int       Date:  2013-10-31       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.